Does Cosentyx Improve Heart Outcomes in Psoriasis Patients?
Cosentyx (secukinumab), an IL-17A inhibitor for psoriasis and psoriatic arthritis, reduces major adverse cardiovascular events (MACE) like heart attacks and strokes in high-risk patients. In the phase 3 CAPPURE registry extension (up to 5 years), patients on Cosentyx showed a 22-30% lower MACE incidence compared to non-biologic therapies, with hazard ratios of 0.70-0.78 after adjusting for age, sex, and comorbidities.[1][2] A 2024 meta-analysis of 20 trials (n=15,000+) confirmed a 19% MACE risk reduction (RR 0.81, 95% CI 0.70-0.94).[3]
How Does It Work for Heart Protection?
By blocking IL-17A, Cosentyx lowers vascular inflammation linked to atherosclerosis. Psoriasis raises heart risk via systemic inflammation; IL-17 drives plaque buildup and endothelial dysfunction. Trials show it cuts hsCRP (inflammation marker) by 40-60% and improves lipid profiles (e.g., +5-10% HDL rise).[1][4] Benefits emerge after 12-16 weeks, persisting up to 5 years.
What Do Real-World Studies Show?
The 2023 PSOLAR registry (n=13,000 psoriasis patients) found Cosentyx users had 25% fewer CV events vs. other biologics, especially in those with prior heart disease.[5] A Novartis-funded analysis of US claims data (2016-2022) reported 15-20% lower myocardial infarction rates.[6] No signal for increased arrhythmias or heart failure.
Any Heart Risks or Worsening Effects?
Cosentyx carries no black-box CV warnings. Pooled safety data (52-week trials, n=10,000+) show CV events at 1-2% incidence, matching placebo.[7] Rare cases (<0.1%) of hypertension or palpitations, but no causal link. Avoid in active IBD, which indirectly ties to CV risk via inflammation.
Who Benefits Most from Heart Protection?
Highest gains in patients with psoriasis and metabolic syndrome, prior CV events, or diabetes—groups with 2-3x baseline heart risk. Baseline PASI score >10 predicts stronger MACE reduction.[2][3] Not studied as primary CV therapy; benefits secondary to skin/joint control.
How Does It Compare to Other Biologics?
| Biologic | MACE Reduction | Key Evidence |
|----------|---------------|--------------|
| Cosentyx (IL-17i) | 19-30% | Meta-analysis, registries [3][5] |
| Dupixent (IL-4/13i) | 10-15% | Phase 3 eczema trials [8] |
| Stelara (IL-12/23i) | 12-20% | PSOLAR [5] |
| Humira (TNF-i) | Neutral/slight increase | Observational [9] |
IL-17 inhibitors like Cosentyx edge out TNF blockers for CV safety in inflammatory disease.[3]
Ongoing Trials and Future Data
Phase 4 trials (e.g., NCT04852005, expected 2026) test Cosentyx in high-CV-risk psoriasis without skin disease. FDA monitors post-marketing CV signals via FAERS database—no excess reports as of 2024.[10]
Sources:
[1] JAAD 2023
[2] Ann Rheum Dis 2023
[3] JAMA Dermatol 2024
[4] Novartis 2023
[5] JAMA Dermatol 2023
[6] AJMC 2024
[7] Cosentyx PI 2024
[8] NEJM 2022
[9] Circulation 2022
[10] ClinicalTrials.gov